{"status":"ok","message-type":"work-list","message-version":"1.0.0","message":{"facets":{},"total-results":1,"items":[{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:40:34Z","timestamp":1767980434553,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.pan.2012.09.004","type":"journal-article","created":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T21:15:35Z","timestamp":1376514935000},"page":"467-474","source":"Crossref","is-referenced-by-count":18,"title":["Polysaccharide-K (PSK) increases p21WAF\/Cip1 and promotes apoptosis in pancreatic cancer cells"],"prefix":"10.1016","volume":"12","author":[{"given":"Ann H.","family":"Rosendahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DeQuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pan.2012.09.004_bib1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/157488409788185007","article-title":"Recent advances and developments in treatment strategies against pancreatic cancer","volume":"4","author":"Fryer","year":"2009","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.pan.2012.09.004_bib2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.bjc.6605190","article-title":"Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by ap-2alpha overexpression","volume":"101","author":"Jonckheere","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pan.2012.09.004_bib3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.seminoncol.2007.05.009","article-title":"Cytotoxic therapy for advanced pancreatic adenocarcinoma","volume":"34","author":"O'Reilly","year":"2007","journal-title":"Semin Oncol"},{"key":"10.1016\/j.pan.2012.09.004_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.pan.2012.09.004_bib5","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMra0901557","article-title":"Pancreatic cancer","volume":"362","author":"Hidalgo","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pan.2012.09.004_bib6","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jama.280.18.1569","article-title":"Trends in alternative medicine use in the united states, 1990\u20131997: results of a follow-up national survey","volume":"280","author":"Eisenberg","year":"1998","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.pan.2012.09.004_bib7","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2000.18.13.2505","article-title":"Complementary\/alternative medicine use in a comprehensive cancer center and the implications for oncology","volume":"18","author":"Richardson","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2012.09.004_bib8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2174\/092986712798992020","article-title":"Polysaccharide-k (psk) in cancer \u2013 old story, new possibilities?","volume":"19","author":"Sun","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.pan.2012.09.004_bib9","first-page":"1737","article-title":"Anticancer effects and mechanisms of polysaccharide-k (psk): implications of cancer immunotherapy","volume":"22","author":"Fisher","year":"2002","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pan.2012.09.004_bib10","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bjc.6601619","article-title":"Adjuvant immunochemotherapy with oral tegafur\/uracil plus psk in patients with stage ii or iii colorectal cancer: a randomised controlled study","volume":"90","author":"Ohwada","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pan.2012.09.004_bib11","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00262-006-0248-1","article-title":"Efficacy of adjuvant immunochemotherapy with polysaccharide k for patients with curative resections of gastric cancer","volume":"56","author":"Oba","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.pan.2012.09.004_bib12","first-page":"71","article-title":"Effect of krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients","volume":"21","author":"Hayakawa","year":"1997","journal-title":"Cancer Detect Prev"},{"key":"10.1016\/j.pan.2012.09.004_bib13","series-title":"ClinicalTrials.gov","year":"2011"},{"key":"10.1016\/j.pan.2012.09.004_bib14","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2004-06-2406","article-title":"Psk and trx80 inhibit b-cell growth in ebv-infected cord blood mononuclear cells through t cells activated by the monocyte products il-15 and il-12","volume":"105","author":"Liu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pan.2012.09.004_bib15","first-page":"1189","article-title":"Psk, a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumor-derived factors in\u00a0vitro","volume":"20","author":"Okuzawa","year":"2002","journal-title":"Int J Oncol"},{"key":"10.1016\/j.pan.2012.09.004_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1158\/1078-0432.CCR-10-1763","article-title":"Polysaccharide krestin is a novel tlr2 agonist that mediates inhibition of tumor growth via stimulation of cd8 t cells and nk cells","volume":"17","author":"Lu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2012.09.004_bib17","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1158\/1078-0432.CCR-11-1142","article-title":"Tlr2 agonist psk activates human nk cells and enhances the anti-tumor effect of her2-targeted monoclonal antibody therapy","volume":"17","author":"Lu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2012.09.004_bib18","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00262-008-0498-1","article-title":"Protein-bound polysaccharide k augments il-2 production from murine mesenteric lymph node cd4+ t cells by modulating t cell receptor signaling","volume":"57","author":"Asai","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.pan.2012.09.004_bib19","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.fitote.2010.06.002","article-title":"Role for toll-like receptor 4 in tnf-alpha secretion by murine macrophages in response to polysaccharide krestin, a trametes versicolor mushroom extract","volume":"81","author":"Price","year":"2010","journal-title":"Fitoterapia"},{"key":"10.1016\/j.pan.2012.09.004_bib20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/cbr.2008.0484","article-title":"Immunochemotherapy with psk and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer","volume":"23","author":"Sakai","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.pan.2012.09.004_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/jjco\/hyl048","article-title":"A\u00a0randomized phase iii trial of postoperative adjuvant therapy with s-1 alone versus s-1 plus psk for stage ii\/iiia gastric cancer: Hokuriku-kinki immunochemo-therapy study group-gastric cancer (hkit-gc)","volume":"36","author":"Ueda","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.pan.2012.09.004_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2407-8-78","article-title":"The immunomodulator psk induces in\u00a0vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis","volume":"8","author":"Jimenez-Medina","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pan.2012.09.004_bib23","first-page":"343","article-title":"Protein-bound polysaccharide psk inhibits tumor invasiveness by down-regulation of tgf-beta1 and mmps","volume":"18","author":"Zhang","year":"2000","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.pan.2012.09.004_bib24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.cell.2011.03.035","article-title":"Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression","volume":"145","author":"Brady","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.pan.2012.09.004_bib25","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0092-8674(00)81728-6","article-title":"Apoptotic pathways: the roads to ruin","volume":"94","author":"Green","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.pan.2012.09.004_bib26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1440-1711.2006.01444.x","article-title":"Immunobiology of toll-like receptors: emerging trends","volume":"84","author":"Pandey","year":"2006","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.pan.2012.09.004_bib27","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.3748\/wjg.v16.i23.2881","article-title":"Expression and significance of tlr4 and hif-1alpha in pancreatic ductal adenocarcinoma","volume":"16","author":"Zhang","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pan.2012.09.004_bib28","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.bcp.2010.05.018","article-title":"Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray","volume":"80","author":"Morse","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pan.2012.09.004_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2007.02.018","article-title":"Cancer relapse under chemotherapy: why tlr2\/4 receptor agonists can help","volume":"563","author":"Garay","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pan.2012.09.004_bib30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/cbr.1997.12.341","article-title":"Direct tumor growth suppressive effect of melanoidin extracted from immunomodulator-psk","volume":"12","author":"Kamei","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.pan.2012.09.004_bib31","doi-asserted-by":"crossref","first-page":"17810","DOI":"10.1074\/jbc.272.28.17810","article-title":"Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress","volume":"272","author":"Lander","year":"1997","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.pan.2012.09.004_bib32","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"Cd40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.pan.2012.09.004_bib33","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/CCO.0b013e3283473610","article-title":"Metastatic pancreatic cancer: old drugs, new paradigms","volume":"23","author":"Conroy","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.pan.2012.09.004_bib34","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1158\/0008-5472.CAN-08-4235","article-title":"Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer","volume":"69","author":"Banerjee","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.pan.2012.09.004_bib35","doi-asserted-by":"crossref","first-page":"9064","DOI":"10.1158\/0008-5472.CAN-05-1330","article-title":"Molecular evidence for increased antitumor activity of gemcitabine by genistein in\u00a0vitro and in\u00a0vivo using an orthotopic model of pancreatic cancer","volume":"65","author":"Banerjee","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.pan.2012.09.004_bib36","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s10637-011-9691-8","article-title":"A\u00a0phase ii randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma","volume":"30","author":"Ko","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.pan.2012.09.004_bib37","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1038\/sj.onc.1206310","article-title":"Psk-mediated nf-kappab inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells nor-p1","volume":"22","author":"Zhang","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.pan.2012.09.004_bib38","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1080\/00365520902745039","article-title":"Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions","volume":"44","author":"Andersson","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.pan.2012.09.004_bib39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.gastro.2008.09.067","article-title":"Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer","volume":"136","author":"Farrell","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pan.2012.09.004_bib40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0165-2478(92)90121-4","article-title":"Activation of human natural killer cells by the protein-bound polysaccharide psk independently of interferon and interleukin 2","volume":"31","author":"Kariya","year":"1992","journal-title":"Immunol Lett"}],"container-title":["Pancreatology"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390312001962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390312001962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T00:32:37Z","timestamp":1563669157000},"score":15.933062,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390312001962"}},"issued":{"date-parts":[[2012,11]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1424390312001962"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2012.09.004","ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"published":{"date-parts":[[2012,11]]}}],"items-per-page":20,"query":{"start-index":0,"search-terms":"S1424390312001962"}}}